IPO registrations (S-1, F-1) · Registrants
Evotec SE
- SEC CIK
- 1412558 · filings on EDGAR ↗
- Former names
- Evotec AG (2007–2021)
- Registration
- Form F-1, first filed 2021-10-08, last 2021-10-29; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2021-11-05; declared effective 2021-11-03
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- 2M
- Business address
- ESSENER BOGEN 7, Hamburg 22419
- Ticker
- EVO, EVOTF (Nasdaq, OTC)
- EDGAR entity type
- other
Offering terms
- Final price
- $21.75 per ADS (424B4 filed 2021-11-05, an initial public offering)
- Shares sold
- 20,000,000
- Gross proceeds
- $435,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol EVO
- Lead underwriters
- BofA Securities; Morgan Stanley (6,500,000 shares)
- Syndicate
- Citigroup; Jefferies (1,750,000); Cowen (1,750,000); RBC Capital Markets (1,750,000); Number of ADSs BofA Securities, Inc (6,500,000); Citigroup Gobal Markets Inc (1,750,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-10-08 | F-1 | F-1 (foreign registration) | Evotec SE | 0001193125-21-295475 ↗ |
| 2021-10-22 | F-1/A | F-1/A (amendment) | Evotec SE | 0001193125-21-304665 ↗ |
| 2021-10-26 | F-1/A | F-1/A (amendment) | Evotec SE | 0001193125-21-307743 ↗ |
| 2021-10-28 | F-1/A | F-1/A (amendment) | Evotec SE | 0001193125-21-310388 ↗ |
| 2021-10-29 | F-1/A | F-1/A (amendment) | Evotec SE | 0001193125-21-312901 ↗ |
| 2021-11-03 | EFFECT | EFFECT (declared effective) | Evotec SE | 9999999995-21-004175 ↗ |
| 2021-11-05 | 424B4 | 424B4 (final prospectus) | Evotec SE | 0001193125-21-321692 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-10-29 | F-1/A | registration statement | 22,000,000 | - | Nasdaq EVO | 7 | primary document; shares headline, cover names 7 | document ↗ | ||
| 2021-11-05 | 424B4 | final prospectus | $21.75 | 20,000,000 | $435,000,000 | Nasdaq EVO | 8 | primary document; price sentence, shares headline, proceeds table, underwriting table 6, cover names 6 | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Others with the same interests
SIC industry Pharmaceutical Preparations:
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
- Biofrontera AG 2M
- CURAXIS PHARMACEUTICAL Corp 2Q
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
Interests: Pharmaceutical Preparations · Health